Pro-Dex’s (PDEX) “Buy” Rating Reiterated at Ascendiant Capital Markets

Ascendiant Capital Markets reissued their buy rating on shares of Pro-Dex, Inc. (NASDAQ:PDEX) in a report released on Friday, September 8th. Ascendiant Capital Markets currently has a $9.00 price target on the medical instruments supplier’s stock, up from their prior price target of $8.00.

Pro-Dex (NASDAQ PDEX) traded down 1.32% on Friday, hitting $7.50. The stock had a trading volume of 27,259 shares. The company has a 50 day moving average price of $6.73 and a 200-day moving average price of $5.69. The company has a market cap of $31.45 million, a price-to-earnings ratio of 6.00 and a beta of -0.42. Pro-Dex has a 52-week low of $3.80 and a 52-week high of $7.90.

ILLEGAL ACTIVITY NOTICE: This report was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://stocknewstimes.com/2017/09/23/pro-dex-inc-pdex-earns-buy-rating-from-ascendiant-capital-markets.html.

About Pro-Dex

Pro-Dex, Inc (Pro-Dex) designs and produces surgical and dental instruments and motion control products used in the medical, factory automation and scientific research industries. The Company operates through four segments: Pro-Dex, OMS, Fineline and Engineering Services Division (ESD). The Pro-Dex segment provides primarily medical and dental instruments using shared production and assembly machines and workforce.




Receive News & Ratings for Pro-Dex Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pro-Dex Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

15 − fourteen =